Core Insights - Yuanqi Biopharmaceuticals has entered a strategic collaboration with Dr. Falk Pharma to co-develop the innovative AhR agonist ATB102 for the treatment of moderate to severe ulcerative colitis (UC) [1][2] - ATB102 is a novel mechanism therapy targeting gastrointestinal inflammation and mucosal damage, currently undergoing Phase I clinical trials in the United States [1][2] Company Overview - Yuanqi Biopharmaceuticals focuses on the research and development of new drugs for inflammatory immune diseases, while Dr. Falk Pharma specializes in the digestive and metabolic fields [1] - The collaboration includes joint development, licensing options, production, and commercialization agreements for ATB102 [1] Product Details - ATB102 is designed to be enriched in the gut, aiming to restore immune homeostasis and promote mucosal barrier repair, with potential anti-fibrotic and antioxidant effects [2] - The drug targets the AhR, a ligand-dependent transcription factor involved in immune balance and barrier function maintenance, which has been linked to inflammatory bowel diseases [2] Market Potential - The partnership allows Dr. Falk Pharma to obtain global exclusive rights for ATB102 outside of Greater China, while Yuanqi Biopharmaceuticals will receive signing fees, milestone payments, and royalties based on sales [1] - The collaboration is expected to accelerate the clinical development process, addressing unmet clinical needs in the ulcerative colitis treatment landscape [2]